CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

761398Orig1s000
761398Orig2s000

REMS

RISK EVALUATION AND MITIGATION STRATEGY (REMS) DOCUMENT
CONEXXENCE (denosumab-bnht) REMS

I. Administrative Information

Risk: Severe hypocalcemia

Application Number: BLA 761398 (and Unbranded Biological Product)

Application Holder: Fresenius Kabi USA, LLC

Initial REMS approval: 03/2025

Most Recent REMS Update: 10/2025

II. REMS Goal

The goal of the CONEXXENCE REMS is to mitigate the risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD) including dialysis-dependent patients associated with CONEXXENCE

Objective 1: Inform healthcare providers on:

- Risk of severe hypocalcemia with advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73 m^2)
- Need to assess for presence of chronic kidney disease-mineral bone disorder (CKD-MBD) before initiating CONEXXENCE in patients with advanced chronic kidney disease

III. REMS Requirements

To inform healthcare providers about the REMS and the risk and safe use of CONEXXENCE, Fresenius Kabi USA, LLC must disseminate REMS communication materials according to the table below:

Target Audience	Communication Materials & Dissemination Plans
Healthcare providers who are likely to prescribe CONEXXENCE	REMS Letters: REMS Letter for Healthcare Providers, REMS Letter for Professional Societies with attachment Prescribing Information. 1. Mail REMS Letter for Healthcare Providers within 60 calendar days of the date CONEXXENCE is first commercially distributed and again 12 months later. a. If returned, attempt to obtain updated address information, and send a second letter by mail within 45 calendar days of the date the first letter is returned. If correct address cannot be obtained, the attempt will be documented.

2. Email REMS Letter for Professional Societies within 60 calendar days of the date CONEXXENCE is first commercially distributed and again 12 months later through the following professional societies and request the letter or content be provided to their members. If the first email is undeliverable, the REMS letter will be mailed within 30 calendar days. If the first email is marked as unopened, a second email will be sent within 7 calendar days. If the second email is undeliverable or marked as unopened, the REMS letter will be mailed within 30 calendar days.
    a. Bone Health and Osteoporosis Foundation
    b. American Society for Bone and Mineral Research
    c. American College of Rheumatology
    d. American Association of Clinical Endocrinology
    e. American Academy of Family Physicians
    f. Endocrine Society
    g. American Society of Clinical Oncology
    h. North American Menopause Society
    i. American College of Physicians
3. Make available via a link from the REMS Website.
4. Disseminate through field-based sales and medical representatives from the date CONEXXENCE is first commercially distributed for the duration of the REMS.
5. Disseminate and prominently display at Professional Meetings where Fresenius Kabi USA, LLC has a CONEXXENCE commercial presence from the date CONEXXENCE is first commercially distributed for the duration of the REMS.

Patient Guide and Prescribing Information (PI)

1. Disseminate and prominently display at Professional Meetings where Fresenius Kabi USA, LLC has a CONEXXENCE commercial presence from the date CONEXXENCE is first commercially distributed for the duration of the REMS.
2. Disseminate through field-based sales and medical representatives during the initial and/or follow-up discussion with healthcare providers from the date CONEXXENCE is first commercially distributed for the duration of the REMS. Field-based sales and/or medical representatives to verbally review the risk messages contained in the Patient Guide and PI during the visit with the healthcare provider.

Website

1. Make the REMS Website fully operational and all REMS materials available through the website by the date CONEXXENCE is first commercially distributed.
2. Maintain the REMS Website from the date CONEXXENCE is first commercially distributed for the duration of the REMS.
3. Include a prominent REMS-specific link to the REMS Website on all product websites for consumers and healthcare providers. The REMS Website must not link back to the promotional product websites.

IV. REMS Assessment Timetable

Fresenius Kabi USA, LLC will submit REMS Assessments to FDA at 18 months, 3 years and 7 years from the date of the initial approval (03/25/2025) of the REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date for that assessment. Fresenius Kabi USA, LLC will submit each assessment so that it will be received by the FDA on or before the due date.

V. REMS Materials

The following materials are part of the CONEXXENCE REMS:

Training and Educational Material

Patient:

1. Patient Guide

Communication Materials

2. REMS Letter for Healthcare Providers

3. REMS Letter for Professional Societies

Other Material

4. REMS Website

VI. Statutory Elements

This REMS is required under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21U.S.C. 355-1) and consists of the following elements:

1. Communication Plan

2. Timetable for Submission of Assessments

CONEXXENCE® (denosumab-bnht)

CONEXXENCE® REMS : Patient Guide

What is CONEXXENCE?

CONEXXENCE is a prescription medicine used to:

- Treat osteoporosis (thinning and weakening of bone) in women after menopause ("change of life") who:
  - Are at high risk for fracture (broken bone)
  - Cannot use another osteoporosis medicine or other osteoporosis medicines did not work well
- Treat to increase bone mass in men with osteoporosis who are at high risk for fracture
- Treat bone loss in men who are at high risk for fracture receiving certain treatments for prostate cancer that has not spread to other parts of the body
- Treat bone loss in women who are at high risk for fracture receiving certain treatments for breast cancer that has not spread to other parts of the body
- Treat osteoporosis in men and women who will be taking corticosteroid medicines (such as prednisone) for at least 6 months and are at high risk of fracture

What is the serious risk of CONEXXENCE?

Patients with advanced chronic kidney disease, including dialysis-dependent patients, are at risk of severe hypocalcemia (low calcium levels in your blood) following CONEXXENCE administration.

Most people with low blood calcium levels do not have symptoms, but some people may have symptoms which include:

- Spasms, twitches, or cramps in your muscles
- Numbness or tingling in your fingers, toes, or around your mouth

Call your doctor right away if you think you may be having any of these symptoms.

What to expect before and during CONEXXENCE Treatment:

- Talk to your doctor before starting CONEXXENCE.
- If you have low blood calcium before you start receiving CONEXXENCE, it may get worse during treatment.
- Your low blood calcium must be treated before you receive CONEXXENCE.
- Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood while you take CONEXXENCE. Take calcium and vitamin D as your doctor tells you to.
- If you have advanced chronic kidney disease (may or may not be on kidney dialysis), CONEXXENCE may increase your risk for severe low calcium levels in your blood, leading to hospitalization, life-threatening events, and death.
- A mineral and bone disorder associated with kidney disease called chronic kidney disease-mineral bone disorder (CKD-MBD) may increase your risk for severe low calcium levels in blood. Before you start CONEXXENCE and during treatment, your doctor may need to do certain blood tests to check for CKD-MBD.

If you have advanced chronic kidney disease, your doctor may coordinate your CONEXXENCE treatment with a healthcare provider with expertise in CKD-MBD.

FRESENIUS KABI

Fresenius Kabi USA, LLC

Three Corporate Drive, Lake Zurich, IL 60047

CONEXXENCE REMS

FDA Required REMS Safety Information

March 2025

Important Safety Update

Dear Healthcare Provider:

The FDA has required this safety information as part of the CONEXXENCE REMS (**R**isk **E**valuation and **M**itigation **S**trategy) to inform healthcare providers about the following **serious risk of CONEXXENCE**:

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m^2), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following CONEXXENCE administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
  - Evaluate for the presence of chronic kidney disease-mineral bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 $(OH)_2$ vitamin D prior to decisions regarding CONEXXENCE treatment.
  - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
  - Monitor serum calcium weekly for the first month after CONEXXENCE administration and monthly thereafter.
  - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ **Provide** each patient with a copy of the **Patient Guide.**
- ✓ **Review information** in the **Patient Guide** with each patient, including the serious risk of CONEXXENCE and the symptoms of severe hypocalcemia.
- ✓ **Advise** each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for CONEXXENCE. Please review the Prescribing Information enclosed. All CONEXXENCE REMS materials are also available at www.conexxencerems.com.

Reporting Adverse Events

To report Adverse Reactions with CONEXXENCE, please call Fresenius Kabi USA, LLC Vigilance at 1-800-551-7176, or report the event at FDA MedWatch.

Sincerely,

Fresenius Kabi USA, LLC

CONEXXENCE REMS

FDA Required REMS Safety Information

March 2025

Important Safety Update

Dear [Professional Society]:

The FDA has required Fresenius Kabi USA, LLC to distribute this safety information to your organization as part of our CONEXXENCE REMS (**R**isk **E**valuation and **M**itigation **S**trategy) program. We request that you inform your members about the following **serious risk of CONEXXENCE**:

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m^2), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following CONEXXENCE administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
  - Evaluate for the presence of chronic kidney disease-mineral bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 $(OH)_2$ vitamin D prior to decisions regarding CONEXXENCE treatment.
  - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
  - Monitor serum calcium weekly for the first month after CONEXXENCE administration and monthly thereafter.
  - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ **Provide** each patient with a copy of the **Patient Guide.**
- ✓ **Review information** in the **Patient Guide** with each patient, including the serious risk of CONEXXENCE and the symptoms of severe hypocalcemia.
- ✓ **Advise** each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for CONEXXENCE. Please review the Prescribing Information enclosed. All CONEXXENCE REMS materials are also available at www.conexxencerems.com.

Reporting Adverse Events

To report Adverse Reactions with CONEXXENCE, please call Fresenius Kabi USA, LLC Vigilance at 1-800-551-7176, or report the event at FDA MedWatch.

Sincerely,

Fresenius Kabi USA, LLC

Conexxence® denosumab-bnht

Important Safety Information Prescribing Information (PDF)

The site is for US Residents only.

CONEXXENCE REMS

What is the CONEXXENCE REMS?

The CONEXXENCE REMS (**R**isk **E**valuation and **M**itigation **S**trategy) is a safety program required by the Food and Drug Administration.

The purpose of the CONEXXENCE REMS is to inform healthcare providers and patients about the risk of:

- Severe hypocalcemia in patients with advanced chronic kidney disease including dialysis-dependent patients, following CONEXXENCE administration

The CONEXXENCE REMS materials are designed to inform healthcare providers and their patients about the risk of severe hypocalcemia associated with CONEXXENCE and include the below materials. It is important that you discuss with your patients the information included in the **Patient Guide.**

- REMS Letter for Healthcare Providers
- Prescribing Information
- Patient Guide

Resources

For Healthcare Providers

- REMS Letter for Healthcare Providers
- Prescribing Information
- Patient Guide

For Patients

- Patient Guide

To learn more about CONEXXENCE, read the Important Safety Information and use the links to access the CONEXXENCE REMS materials.

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Healthcare providers should report all suspected adverse events associated with CONEXXENCE to the FDA or to Fresenius Kabi USA, LLC at 1-800-551-7176.

FRESENIUS KABI

CONEXXENCE REMS

Contact Us

If you have any questions about the REMS, a clinical inquiry, or would like to report an adverse event related to CONEXXENCE

Call Fresenius Kabi at 1-800-551-7176

For adverse events, email
adverse.events.usa@fresenius-kabi.com

For clinical inquiries, email
biosimilars.medinfo.usa@fresenius-kabi.com

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA E KEHOE
10/29/2025 11:22:50 AM

CHRISTY L OSGOOD
10/29/2025 12:59:34 PM

RISK EVALUATION AND MITIGATION STRATEGY (REMS)
CONEXXENCE (denosumab-bnht) REMS

I. Administrative Information

Risk: Severe hypocalcemia

Application Number: BLA 761398 (and Unbranded Biological Product)

Application Holder: Fresenius Kabi USA, LLC

Initial REMS approval: 03/2025

II. REMS Goal

The goal of the CONEXXENCE REMS is to mitigate the risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD) including dialysis-dependent patients associated with CONEXXENCE

Objective 1: Inform healthcare providers on:

- Risk of severe hypocalcemia with advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73 m^2)
- Need to assess for presence of chronic kidney disease-mineral bone disorder (CKD-MBD) before initiating CONEXXENCE in patients with advanced chronic kidney disease

III. REMS Elements

To inform healthcare providers about the REMS and the risk and safe use of CONEXXENCE, Fresenius Kabi USA, LLC must disseminate REMS communication materials according to the table below:

Target Audience	Communication Materials & Dissemination Plans
Healthcare providers who are likely to prescribe CONEXXENCE	REMS Letters: REMS Letter for Healthcare Providers, REMS Letter for Professional Societies with attachment Prescribing Information. 1. Mail REMS Letter for Healthcare Providers within 60 calendar days of the date CONEXXENCE is first commercially distributed and again 12 months later. a. If returned, attempt to obtain updated address information, and send a second letter by mail within 45 calendar days of the date the first letter is returned. If correct address cannot be obtained, the attempt will be documented. 2. Email REMS Letter for Professional Societies within 60 calendar days of the date CONEXXENCE is first commercially distributed and again 12 months later through the following professional societies and request the letter or content be provided to their members. If the first email is undeliverable, the REMS letter will be mailed within 30 calendar days. If the first email is marked as unopened, a second email will be sent within 7 calendar days. If the second email is undeliverable or marked as unopened, the REMS letter will be mailed within 30 calendar days.

a. Bone Health and Osteoporosis Foundation
b. American Society for Bone and Mineral Research
c. American College of Rheumatology
d. American Association of Clinical Endocrinology
e. American Academy of Family Physicians
f. Endocrine Society
g. American Society of Clinical Oncology
h. North American Menopause Society
i. American College of Physicians

3. Make available via a link from the REMS Website.
4. Disseminate through field-based sales and medical representatives from the date CONEXXENCE is first commercially distributed for the duration of the REMS.
5. Disseminate and prominently display at Professional Meetings where Fresenius Kabi USA, LLC has a CONEXXENCE commercial presence from the date CONEXXENCE is first commercially distributed for the duration of the REMS.

Patient Guide and Prescribing Information (PI)

1. Disseminate and prominently display at Professional Meetings where Fresenius Kabi USA, LLC has a CONEXXENCE commercial presence from the date CONEXXENCE is first commercially distributed for the duration of the REMS.
2. Disseminate through field-based sales and medical representatives during the initial and/or follow-up discussion with healthcare providers from the date CONEXXENCE is first commercially distributed for the duration of the REMS. Field-based sales and/or medical representatives to verbally review the risk messages contained in the Patient Guide and PI during the visit with the healthcare provider.

Website

1. Make the REMS Website fully operational and all REMS materials available through the website by the date CONEXXENCE is first commercially distributed.
2. Maintain the REMS Website from the date CONEXXENCE is first commercially distributed for the duration of the REMS.
3. Include a prominent REMS-specific link to the REMS Website on all product websites for consumers and healthcare providers. The REMS Website must not link back to the promotional product websites.

IV. REMS Assessment Timetable

Fresenius Kabi USA, LLC will submit REMS Assessments to FDA at 18 months, 3 years and 7 years from the date of the initial approval (DD MM YYYY) of the REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date for that assessment. Fresenius Kabi USA, LLC will submit each assessment so that it will be received by the FDA on or before the due date.

V. REMS Materials

The following materials are part of the CONEXXENCE REMS:

Training and Educational Material

Patient:

1. Patient Guide

Communication Materials

2. REMS Letter for Healthcare Providers

3. REMS Letter for Professional Societies

Other Material

4. REMS Website

VI. Statutory Elements

This REMS is required under section 505-1 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21U.S.C. 355-1) and consists of the following elements:

1. Communication Plan

2. Timetable for Submission of Assessments

Conexxence®
denosumab-bnht

CONEXXENCE® (denosumab-bnht)

CONEXXENCE® REMS : Patient Guide

What is CONEXXENCE?

CONEXXENCE is a prescription medicine used to:

- Treat osteoporosis (thinning and weakening of bone) in women after menopause ("change of life") who:
  - Are at high risk for fracture (broken bone)
  - Cannot use another osteoporosis medicine or other osteoporosis medicines did not work well
- Treat to increase bone mass in men with osteoporosis who are at high risk for fracture
- Treat bone loss in men who are at high risk for fracture receiving certain treatments for prostate cancer that has not spread to other parts of the body
- Treat bone loss in women who are at high risk for fracture receiving certain treatments for breast cancer that has not spread to other parts of the body
- Treat osteoporosis in men and women who will be taking corticosteroid medicines (such as prednisone) for at least 6 months and are at high risk of fracture

What is the serious risk of CONEXXENCE?

Patients with advanced chronic kidney disease, including dialysis-dependent patients, are at risk of severe hypocalcemia (low calcium levels in your blood) following CONEXXENCE administration.

Most people with low blood calcium levels do not have symptoms, but some people may have symptoms which include:

- Spasms, twitches, or cramps in your muscles
- Numbness or tingling in your fingers, toes, or around your mouth

Call your doctor right away if you think you may be having any of these symptoms.

What to expect before and during CONEXXENCE Treatment:

- Talk to your doctor before starting CONEXXENCE.
- If you have low blood calcium before you start receiving CONEXXENCE, it may get worse during treatment.
- Your low blood calcium must be treated before you receive CONEXXENCE.
- Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood while you take CONEXXENCE. Take calcium and vitamin D as your doctor tells you to.
- If you have advanced chronic kidney disease (may or may not be on kidney dialysis), CONEXXENCE may increase your risk for severe low calcium levels in your blood, leading to hospitalization, life-threatening events, and death.
- A mineral and bone disorder associated with kidney disease called chronic kidney disease-mineral bone disorder (CKD-MBD) may increase your risk for severe low calcium levels in blood. Before you start CONEXXENCE and during treatment, your doctor may need to do certain blood tests to check for CKD-MBD.

If you have advanced chronic kidney disease, your doctor may coordinate your CONEXXENCE treatment with a healthcare provider with expertise in CKD-MBD.

FRESENIUS KABI

Fresenius Kabi USA, LLC

Three Corporate Drive, Lake Zurich, IL 60047

Reference ID: XXXXXXX

CONEXXENCE REMS

FDA Required REMS Safety Information

Month YYYY

Important Safety Update

Dear Healthcare Provider:

The FDA has required this safety information as part of the CONEXXENCE REMS (Risk Evaluation and Mitigation Strategy) to inform healthcare providers about the following serious risk of CONEXXENCE:

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m^2), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following CONEXXENCE administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
  - Evaluate for the presence of chronic kidney disease-mineral bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 $(OH)_2$ vitamin D prior to decisions regarding CONEXXENCE treatment.
  - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
  - Monitor serum calcium weekly for the first month after CONEXXENCE administration and monthly thereafter.
  - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ Provide each patient with a copy of the Patient Guide.
- ✓ Review information in the Patient Guide with each patient, including the serious risk of CONEXXENCE and the symptoms of severe hypocalcemia.
- ✓ Advise each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for CONEXXENCE. Please review the Prescribing Information enclosed. All CONEXXENCE REMS materials are also available at www.proprietarynamerems.com.

Reporting Adverse Events

To report Adverse Reactions with CONEXXENCE, please call Fresenius Kabi USA, LLC Vigilance at 1-800-551-7176, or report the event at FDA MedWatch.

Sincerely,

Fresenius Kabi USA, LLC

Reference ID: xxxxxx

FDA Required REMS Safety Information

Month YYYY

Important Safety Update

Dear [Professional Society]:

The FDA has required Fresenius Kabi USA, LLC to distribute this safety information to your organization as part of our CONEXXENCE REMS (Risk Evaluation and Mitigation Strategy) program. We request that you inform your members about the following serious risk of CONEXXENCE:

Severe Hypocalcemia in Patients with Advanced Kidney Disease

Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m^2), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following CONEXXENCE administration.

- Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported.
- To minimize the risk of hypocalcemia in patients with advanced chronic kidney disease (CKD):
  - Evaluate for the presence of chronic kidney disease-mineral bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 $(OH)_2$ vitamin D prior to decisions regarding CONEXXENCE treatment.
  - Consider assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present.
  - Monitor serum calcium weekly for the first month after CONEXXENCE administration and monthly thereafter.
  - Coordinate care with healthcare providers with expertise in CKD-MBD for patients with advanced chronic kidney disease.

Role of the Healthcare Provider

- ✓ Provide each patient with a copy of the Patient Guide.
- ✓ Review information in the Patient Guide with each patient, including the serious risk of CONEXXENCE and the symptoms of severe hypocalcemia.
- ✓ Advise each patient to seek prompt medical attention if they have signs or symptoms of severe hypocalcemia.

This letter does not contain the complete safety profile for CONEXXENCE. Please review the Prescribing Information enclosed. All CONEXXENCE REMS materials are also available at www.proprietarynamerems.com.

Reporting Adverse Events

To report Adverse Reactions with CONEXXENCE, please call Fresenius Kabi USA, LLC Vigilance at 1-800-551-7176, or report the event at FDA MedWatch.

Sincerely,

Fresenius Kabi USA, LLC

Reference ID: xxxxxx

CONEXXENCE REMS

What is the CONEXXENCE REMS?

The CONEXXENCE REMS (**R**isk **E**valuation and **M**itigation **S**trategy) is a safety program required by the Food and Drug Administration.

The purpose of the CONEXXENCE REMS is to inform healthcare providers and patients about the risk of:

- Severe hypocalcemia in patients with advanced chronic kidney disease including dialysis-dependent patients, following CONEXXENCE administration

The CONEXXENCE REMS materials are designed to inform healthcare providers and their patients about the risk of severe hypocalcemia associated with CONEXXENCE and include the below materials. It is important that you discuss with your patients the information included in the **Patient Guide.**

- REMS Letter for Healthcare Providers
- Prescribing Information
- Patient Guide

Resources

For Healthcare Providers

- REMS Letter for Healthcare Providers
- Prescribing Information
- Patient Guide

For Patients

- Patient Guide

To learn more about CONEXXENCE, read the Important Safety Information and use the links to access the CONEXXENCE REMS materials.

Reporting Adverse Events

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Healthcare providers should report all suspected adverse events associated with CONEXXENCE to the FDA or to Fresenius Kabi USA, LLC at 1-800-551-7176.

CONEXXENCE REMS

Contact Us

If you have any questions about the REMS, a clinical inquiry, or would like to report an adverse event related to CONEXXENCE

Call Fresenius Kabi at 1-800-551-7176

For adverse events, email
adverse.events.usa@fresenius-kabi.com

For clinical inquiries, email
biosimilars.medinfo.usa@fresenius-kabi.com

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA E KEHOE
03/25/2025 10:24:27 AM

CHRISTY L OSGOOD
03/25/2025 10:25:15 AM